Résumé
The Brazilian Amazon Region is a highly endemic area for hepatitis B virus (HBV). However, little is known regarding the genetic variability of the strains circulating in this geographical region. Here, we describe the first full-length genomes of HBV isolated in the Brazilian Amazon Region; these genomes are also the first complete HBV subgenotype D3 genomes reported for Brazil. The genomes of the five Brazilian isolates were all 3,182 base pairs in length and the isolates were classified as belonging to subgenotype D3, subtypes ayw2 (n = 3) and ayw3 (n = 2). Phylogenetic analysis suggested that the Brazilian sequences are not likely to be closely related to European D3 sequences. Such results will contribute to further epidemiological and evolutionary studies of HBV.
Sujets)
Humains , Carcinome hépatocellulaire , Mouvement cellulaire/physiologie , Tumeurs du foie , Matrix metalloproteinase 9/génétique , Transduction du signal/physiologie , Inhibiteur tissulaire de métalloprotéinase-1/génétique , Lignée cellulaire tumorale/cytologie , Lignée cellulaire tumorale/physiologie , Collagenases/génétique , Dipeptides/pharmacologie , Inhibiteurs de métalloprotéinases matricielles , Matrix metalloproteinase 1/génétique , /génétique , /génétique , /génétique , Inhibiteurs de protéases/pharmacologie , Transduction du signal/effets des médicaments et des substances chimiques , TransfectionRésumé
Hepatitis B virus (HBV) molecular profiles were determined for 44 patients who were infected with human immunodeficiency virus (HIV) type 1 and had antibodies to the hepatitis B core antigen (anti-HBc), with and without other HBV serological markers. In this population, 70 percent of the patients were under lamivudine treatment as a component of antiretroviral therapy. HBV DNA was detected in 14 (32 percent) patients. Eight out of 12 (67 percent) HBsAg positive samples, 3/10 (30 percent) anti-HBc only samples, and 3/22 (14 percent) anti-HBs positive samples were HBV DNA positive. HBV DNA loads, measured by real time polymerase chain reaction, were much higher in the HBsAg positive patients (mean, 2.5 Î 10(9) copies/ml) than in the negative ones (HBV occult infection; mean, 2.7 Î 10(5) copies/ml). Nine out of the 14 HBV DNA positive patients were under lamivudine treatment. Lamivudine resistant mutations in the polymerase gene were detected in only three patients, all of them belonging to the subgroup of five HBsAg positive, HBV DNA positive patients. A low mean HBV load (2.7 Î 10(5) copies/ml) and an absence of lamivudine resistant mutations were observed among the cases of HBV occult infection.